Cash Flow Statement (Annual)

LNT / Alliant Energy Corp. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss 129,700 306,300 321,900 335,700 376,200 393,300 388,400 381,700 467,500
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Adjustment Depreciation And Amortization Including Discontinued Operations 275,600 292,300 323,800 332,900 370,900 388,100 401,300 411,600 461,800
    Depreciation And Amortization Cash Flow - - - - - - - - -
    Deferred Income Taxes And Tax Credits 94,300 216,600 10,200 143,300 108,300 55,200 114,200 84,600 139,600
    Other Noncash Income Expense 5,700 4,700 5,200 2,600 3,700 -2,000 -15,700 -800 -6,700
  Increase Decrease In Operating Capital
    Increase Decrease In Accounts Receivable -73,500 -16,300 54,300 -61,300 49,200 -48,700 -36,800 121,400 -29,600
    Increase Decreasein Gas Stored Underground - - - - - - - - -
    Increase Decrease In Other Regulatory Assets 163,900 20,800 413,100 178,100 -140,500 439,800 104,500 3,600 130,800
    Increase Decrease In Derivative Assets - - - - - - - - -
    Increase Decrease In Accounts Payable - - - - - - - - -
    Increase Decrease In Regulatory Liabilities 136,700 8,400 168,300 16,400 -90,800 10,800 -67,800 -63,000 -83,800
    Increase Decrease In Deferred Income Taxes -118,900 -28,900 -148,500 -69,700 -101,900 -138,400 -94,600 -102,400 -81,700
    Increase Decrease In Other Operating Capital Net -10,400 -12,200 -21,100 14,200 -23,700 -59,700 -24,700 -22,500 -38,700
  Net Cash Provided By Used In Operating Activities 657,100 984,900 702,700 841,100 731,000 891,600 871,200 859,600 983,400
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Productive Assets Business Line1 1,149,600 0 608,100 403,500 0 0 - - -
  Payments To Acquire Productive Assets Business Line2 53,000 33,600 65,300 132,600 66,700 63,900 74,000 65,600 185,100
  Proceeds From Collection Of Retained Interest In Securitized Receivables - - - - - - - - -
  Payments For Proceeds From Other Investing Activities 16,600 16,700 4,600 19,900 18,800 14,900 24,800 -10,300 29,400
  Net Cash Provided By Used In Investing Activities -1,148,900 -866,500 -652,100 -1,155,500 -754,700 -917,700 -919,200 -1,186,500 -1,496,300
Net Cash Provided By Used In Financing Activities
  Payments Of Dividends Common Stock 165,500 174,600 188,100 199,300 208,300 225,800 247,300 266,500 288,300
  Proceeds From Repayments Of Short Term Debt 103,900 -142,600 55,400 164,700 11,900 -138,100 18,500 84,300 171,100
  Proceeds From Payments For Other Financing Activities -21,800 9,300 -8,100 -8,900 -28,800 -7,100 6,800 -1,700 -45,200
  Net Cash Provided By Used In Financing Activities 320,200 -134,400 -198,500 324,200 12,300 73,200 -3,100 329,300 532,600
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - - - - - -
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations - - - - - - - - -
Supplemental Cash Flow Information
  Interest Paid Net 142,400 165,500 157,600 155,200 171,700 180,800 184,800 192,400 212,600
  Income Taxes Paid Net -140,700 -116,200 -10,800 -20,300 -9,600 -5,300 0 9,800 11,300
  Cash Flow Noncash Investing And Financing Activities Disclosure
    Capital Expenditures Incurred But Not Yet Paid 66,700 75,000 49,700 105,300 103,800 160,300 148,300 154,400 196,500
    Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset - - - - - - - - -

Peers - Electric and Other Services Combined (4931)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 018802108